Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: role of BRCA1.

Current cancer drug targets - 1 May 2009

Stordal Britta, Davey Ross

Abstract excerpt

A systematic review of cell models of acquired drug resistance not involving genetic manipulation showed that 80% of cell models had an inverse resistance relationship between cisplatin and paclitaxel. Here we systematically review genetically modified cell lines in which the inverse cisplatin/paclitaxel resistance phenotype has resulted. This will form a short list of genes which may play a role in the mechanism...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to ATP Binding Cassette Transporter, Subfamily B, Member 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA1 Protein

Share to Cisplatin

Share to Genes, BRCA1

Share to Neoplasms

Share to Oxidoreductases

Share to Paclitaxel

Source

Identifiers

PMID: 19442054
DOI: 10.2174/156800909788166592

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: role of BRCA1.PMID 19442054Read ↗

A quantitative chemotherapy genetic interaction map reveals new factors associated with PARP inhibitor resistanceSemantic proximity Read ↗

Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicinSemantic proximity Read ↗

Microarray-based detection and expression analysis of new genes associated with drug resistance in ovarian cancer cell linesSemantic proximity Read ↗

Cisplatin resistance: Preclinical findings and clinical implicationsSemantic proximity Read ↗

Key genes and molecular mechanisms related to Paclitaxel ResistanceSemantic proximity Read ↗

Common biological phenotypes characterize the acquisition of platinum-resistance in epithelial ovarian cancer cells.Semantic proximity Read ↗

Cross-resistance of cisplatin selected cells to anti-microtubule agents: Role of general survival mechanismsSemantic proximity Read ↗

BRCA2-Deficient Sarcomatoid Mammary Tumors Exhibit Multidrug ResistanceSemantic proximity Read ↗

Altered ErbB Receptor Signaling and Gene Expression in Cisplatin-Resistant Ovarian CancerSemantic proximity Read ↗

Carboplatin and taxol resistance develops more rapidly in functional BRCA1 compared to dysfunctional BRCA1 ovarian cancer cells.Semantic proximity Read ↗

Effect of ALDH1A1 Gene Knockout on Drug Resistance in Paclitaxel and Topotecan Resistant Human Ovarian Cancer Cell Lines in 2D and 3D ModelSemantic proximity Read ↗

Resistance to Paclitaxel in a Cisplatin-Resistant Ovarian Cancer Cell Line Is Mediated by P-GlycoproteinSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.